Ceretrieve Overview
Ceretrieve has designed and developed CathTrap, a neurothrombectomy system with integrated embolic protection for ischemic stroke endovascular treatment. CathTrap provides physicians with a safe, easy-to-use device to prevent distal embolization during thrombectomy procedures for better treatment efficiency and improved clinical outcomes for patients. Ceretrieves aspiration catheter has an expandable soft tip that can enlarge its diameter from 6F to the clot size in order to provide a powerful aspiration force to extract and ingest the clot without compromising trackability in reaching the clot. Ceretrieve is a portfolio company of Trendlines.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Amir Belson appointed as Ceretrieve Chairman following $1.5 million investment round
Ceretrieve, a company focusing on stroke patients, has appointed Amir Belson as chairman following a new round of $1.5 million in funding. The company has designed an aspiration catheter to prevent the dislodgement of clots in ischemic stroke patients. The funding will support the companys efforts towards first in human clinical studies and the development of a neurothrombectomy system for ischemic stroke treatment.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $1.5M |
| Last funding | Undisclosed |
| Stage | Seed |
| Rounds | 2 |
| Investors | 4 |
Team Members
4
Employees: 11-50
Web & Social Links
| Website | www.ceretrieve.com |
Locations
Misgav Regional Council, Israel
Photos & Videos
No files yet
